Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antibacterial agents in pediatrics.

V H San Joaquin1, T L Stull

  • 1Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, USA.

Infectious Disease Clinics of North America
|June 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

'Haptoglobin concentrations in preterm and term newborns'.

Journal of perinatology : official journal of the California Perinatal Association·2011
Same author

Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR.

Journal of clinical microbiology·2000
Same author

Caring for Oklahoma's children: the Department of Pediatrics and Children's Hospital of Oklahoma.

The Journal of the Oklahoma State Medical Association·2000
Same author

Identification of members of the Burkholderia cepacia complex by species-specific PCR.

Journal of clinical microbiology·2000
Same author

A prolonged outbreak of Pseudomonas aeruginosa in a neonatal intensive care unit: did staff fingernails play a role in disease transmission?

Infection control and hospital epidemiology·2000
Same author

Species-specific PCR as a tool for the identification of Burkholderia gladioli.

Journal of clinical microbiology·2000
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

Pediatric antibacterial drug use differs due to unique pharmacokinetics and pharmacodynamics from infancy to adolescence. This review covers key principles and clinical applications for treating pediatric infections.

Area of Science:

  • Pediatric Pharmacology
  • Infectious Diseases
  • Antibacterial Agents

Background:

  • Physiologic and developmental variations in children significantly impact drug behavior.
  • Conditions like cystic fibrosis can further alter drug absorption, distribution, metabolism, and excretion.
  • Understanding these pediatric-specific factors is crucial for effective treatment.

Purpose of the Study:

  • To outline the pharmacokinetic and pharmacodynamic principles unique to pediatric patients.
  • To guide the clinical application of antibacterial agents in treating childhood infectious diseases.

Main Methods:

  • Review of existing literature on pediatric pharmacokinetics and pharmacodynamics.
  • Analysis of how age-related differences affect drug disposition and response.

Related Experiment Videos

  • Discussion of specific antibacterial agents used in pediatric infectious diseases.

    • Main Results:

    • Antibacterial agent pharmacokinetics and pharmacodynamics vary significantly across pediatric age groups.
    • Disease states, such as cystic fibrosis, necessitate tailored dosing strategies.
    • Age-appropriate dosing and drug selection are critical for optimizing treatment outcomes.

    Conclusions:

    • Pediatric-specific pharmacokinetic and pharmacodynamic considerations are essential for safe and effective antibacterial therapy.
    • Tailoring treatment based on individual patient factors ensures optimal management of infectious diseases in children.
    • This knowledge supports evidence-based clinical practice in pediatric infectious disease management.